^
    Back
    Association details:
    Biomarker:HER-2 G660D + HER-2 S310F
    Cancer:Ampulla of Vater Carcinoma
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    The Oncologist
    Title:

    Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E

    Excerpt:
    We also encountered a patient with ampullary adenocarcinoma with ERBB2 G660D and S310F comutations in another institute of the authors’, revealed by comprehensive genomic profiling. This patient was then treated with afatinib and also achieved transitory response.
    DOI:
    10.1634/theoncologist.2017-0345